# EDGAR Filing Document

**Accession Number:** 0001827090
**File Stem:** 0001827090-26-000008
**Filing Date:** 2026-2
**Character Count:** 43198
**Document Hash:** 7078646d46c0ae62ae57882735deca4f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001827090-26-000008.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001827090-26-000008

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260226

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Certara, Inc.
- **CENTRAL INDEX KEY:** 0001827090
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39799
- **FILM NUMBER:** 26681543

**BUSINESS ADDRESS:**
- **STREET 1:** 4 RADNOR CORPORATE CENTER, SUITE 350
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (415) 237-8272

**MAIL ADDRESS:**
- **STREET 1:** 4 RADNOR CORPORATE CENTER, SUITE 350
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087

?xml version='1.0' encoding='ASCII'? certara-20260226

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 26, 2026**

**Certara, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **001-39799** | **82-2180925** |
| (State or other jurisdiction<br>of incorporation) | (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |
| **4 Radnor Corporate Center** | **4 Radnor Corporate Center** | | |
| **Suite 350** | **Suite 350** | | |
| **Radnor,** | **Pennsylvania** | | **19087** |
| (Address of principal executive offices) | (Address of principal executive offices) | | (Zip Code) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **(415) 237-8272**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| Common stock, par value $0.01 per share | CERT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company, as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02**&nbsp;&nbsp;&nbsp;&nbsp; **Results of Operations and Financial Condition.**

On February 26, 2026, Certara, Inc. (the "Company") issued a press release announcing its financial results for the three-month period ended December 31, 2025. A copy of the press release containing the announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit No. | Description |
| <br><u>[99.1\*](q42025earningsreleaseex99.htm)</u> | <u>[Press Release dated February 26, 2026.](q42025earningsreleaseex99.htm)</u> |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL). |

---

\* Furnished herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date:  | February 26, 2026 | CERTARA, INC. | CERTARA, INC. |
|  |  | (Registrant) | (Registrant) |
|  |  | By: | /s/ Daniel Corcoran |
|  |  |  | Daniel Corcoran |
|  |  |  | Senior Vice President and General Counsel |

---

## Ex-99

 **Exhibit 99.1**

**Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance**

*FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth)*

*Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline)*

*FY 2026 Revenue Growth of 0-4%*

*FY 2026 Adjusted EBITDA Margin of 30-32%*

*FY 2026 Adjusted Diluted EPS of $0.44-$0.48*

RADNOR, PA— February 26, 2026-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its fourth quarter and full fiscal year 2025 financial results.

**Fourth Quarter Highlights:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Appointment of Jon Resnick as Chief Executive Officer and Member of the Board of Directors, effective January 1st, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue was $103.6 million, compared to $100.4 million in the fourth quarter of 2024, representing growth of 3%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Software revenue was $46.4 million, compared to $42.3 million in the fourth quarter of 2024, representing growth of 10%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Services revenue was $57.3 million, compared to $58.1 million in the fourth quarter of 2024, representing a decrease of 1%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss was $5.9 million, compared to a net income of $6.6 million in the fourth quarter of 2024, representing a decrease of 190%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA was $32.5 million, compared to $33.5 million in the fourth quarter of 2024, representing a decrease of 3%.

"I am excited to join Certara, the market leader in the fast-growing, high-impact fields of AI-enabled biosimulation and model-informed drug development," said Jon Resnick, Chief Executive Officer. "In my first 60 days, I have been genuinely impressed by the power of our technology, the depth of our customer relationships, and the strength of our people,. It's clear that this company - and this market opportunity - have the foundation required for long-term success."

"To fully realize our potential, over the course of 2026 we will sharpen our strategic focus, accelerate innovation across our product portfolio, and elevate our commercial execution. It will be a year of transition and

------

investment as we put the right people, processes, and structure in place to position the company to better capture the significant market opportunities and enable the company to drive stronger and sustainable growth."

"Our full year and fourth quarter revenue performance was in-line with our expectations on both a reported and organic basis. Adjusted EBITDA margin was 32% for the year, at the high end of our plan, driven by operating efficiencies while maintaining investment in R&D.," said John Gallagher, Chief Financial Officer. "As we look forward into 2026, we expect end markets to remain stable, and we anticipate a number of changes and initiatives over the course of 2026 to drive improving revenue growth through the year, and to better position us for sustained long term growth."

**Fourth Quarter 2025 Results** 

Total revenue for the fourth quarter of 2025 was $103.6 million, representing year-over-year growth of 3% on a reported basis and 2% on a constant currency basis. The overall increase in revenue was primarily driven by the growth in our biosimulation software and services portfolio. Please see note (1) in the section titled "A Note on Non-GAAP Financial Measures" below for more information on constant currency revenue.

Software revenue for the fourth quarter of 2025 was $46.4 million, representing year-over-year growth of 10% on a reported basis and 8% on a constant currency basis. Software growth was driven by contribution from biosimulation software.

Services revenue for the fourth quarter of 2025 was $57.3 million, representing a year-over-year decrease of 1% on a reported basis and 2% on a constant currency basis. Service revenue declined modestly, reflecting normal seasonal fluctuations, while service bookings increased significantly, supporting continued revenue momentum.

Total Bookings for the fourth quarter of 2025 were $155.2 million representing year-over-year growth of 7%.

Software Bookings for the fourth quarter of 2025 were $56.1 million, representing a year-over-year decrease of 6%. The decrease in software bookings was mainly attributable to external factors and execution challenges.

Services Bookings for the fourth quarter of 2025 were $99.1 million, representing year-over-year growth of 17%. The increase in service bookings was primarily driven by growth across all customer tiers, including large, mid-sized, and small customers.

Total cost of revenues for the fourth quarter of 2025 was $39.2 million, an increase of $0.9 million from $38.3 million in the fourth quarter of 2024, primarily attributable to higher software amortization expense and increased professional and consulting costs.

Total operating expenses for the fourth quarter of 2025 were $63.6 million, which increased by $7.5 million from $56.1 million in the fourth quarter of 2024. Higher operating expenses were primarily due to a $7.0

------

million increase in employee-related costs, a $0.8 million increase in equipment and software expenses, a $0.8 million increase in professional and consulting expenses, and a $0.7 million increase in transaction expenses, primarily related to refinancing of our term loan, partially offset by lower state business taxes, higher capitalized R&D costs, and a lower provision for credit allowance.

Net loss for the fourth quarter of 2025 was $5.9 million, compared to a net income of $6.6 million in the fourth quarter of 2024. The $12.5 million decrease in net income was primarily driven by higher operating expenses, increased tax expenses, and increased cost of revenues, partially offset by higher revenues.

Diluted earnings per share for the fourth quarter of 2025 was $(0.04), as compared to diluted earnings per share of $0.04 in the fourth quarter of 2024.

Adjusted EBITDA for the fourth quarter of 2025 was $32.5 million compared to $33.5 million for the fourth quarter of 2024, a decrease of $1.1 million. See note (2) in the section titled "A Note on Non-GAAP Financial Measures" below for more information on adjusted EBITDA.

Adjusted net income for the fourth quarter of 2025 was $14.9 million compared to $24.7 million for the fourth quarter of 2024, a decrease of $9.8 million. Adjusted diluted earnings per share for the fourth quarter of 2025 was $0.09, compared to $0.15 for the fourth quarter of 2024. See note (3) in the section titled "A Note on Non-GAAP Financial Measures" below for more information on adjusted net income and adjusted diluted earnings per share.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED DECEMBER 31,** | **THREE MONTHS ENDED DECEMBER 31,** | **TWELVE MONTHS ENDED DECEMBER 31,** | **TWELVE MONTHS ENDED DECEMBER 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| *<u>Key Financials</u>* | <u>(in millions, except per share data)</u> | <u>(in millions, except per share data)</u> | <u>(in millions, except per share data)</u> | <u>(in millions, except per share data)</u> |
| Revenue | $103.6  | $100.4  | $418.8  | $385.1  |
| Software revenue | $46.4  | $42.3  | $183.3  | $155.7  |
| Service revenue | $57.3  | $58.1  | $235.6  | $229.5  |
| Total bookings | $155.2  | $144.5  | $482.1  | $445.3  |
| Software bookings | $56.1  | $59.7  | $184.3  | $169.4  |
| Service bookings | $99.1  | $84.8  | $297.7  | $275.9  |
| Net income (loss) | $(5.9) | $6.6  | $(1.6) | $(12.1) |
| Diluted earnings per share | $(0.04) | $0.04  | $(0.01) | $(0.08) |
| Adjusted EBITDA | $32.5  | $33.5  | $134.5  | $122.0  |
| Adjusted net income | $14.9  | $24.7  | $70.9  | $72.9  |
| Adjusted diluted earnings per share | $0.09  | $0.15  | $0.44  | $0.45  |
| Cash and cash equivalents |  |  | $189.4  | $179.2  |

---

------

**2026 Financial Outlook**

Certara is providing its guidance for the full year 2026:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Full year 2026 revenue is expected to grow in the range of 0-4%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Full year adjusted EBITDA margin to be approximately 30-32%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Full year adjusted diluted earnings per share is expected to be in the range of $0.44- $0.48.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Fully diluted shares are expected to be in the range of 160 million to 162 million.

Please note that the Company has not reconciled adjusted EBITDA, adjusted EBITDA margin or adjusted diluted earnings per share forward-looking guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

**Webcast and Conference Call Details**

Certara will host a conference call today, February 26, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full fiscal year 2025 financial results. Investors interested in listening to the conference call are required to register online in advance of the call. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com.

**About Certara**

Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.

Please visit our website at www.certara.com. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.

Such disclosures will be included in the Investor Relations section of our website at https://ir.certara.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts.

------

**Forward-Looking Statements**

This press release contains certain statements that constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, with respect to the Company's full-year guidance, the stability of end markets, the Company's ability to improve execution and drive long-term growth, and the Company's future business and financial performance, revenue, margin, and bookings. These statements typically contain words such as "believe," "may," "potential," "will," "plan," "could," "estimate," "expects" and "anticipates" or the negative of these words or other similar terms or expressions. Any statement in this press release that is not a statement of historical fact is a forward-looking statement and involves significant risks and uncertainties. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. You should not rely upon forward-looking statements as predictions of future events and actual results, events, or circumstances. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development; our ability to compete within our market; changes or delays in government regulation relating to the biopharmaceutical industry; trends in research and development spending; operational disruptions, funding constraints and policy changes at the Food and Drug Administration and other government agencies; consolidation within the biopharmaceutical industry; our ability to increase successfully our customer base, expand relationships and the products and services we provide and enter new markets; our ability to retain key personnel or recruit additional qualified personnel; risks related to the mischaracterization of our independent contractors; any delays or defects in our release of new or enhanced software or other biosimulation tools; issues relating to implementation, use and development of artificial intelligence and machine learning in our products and services; failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by our existing customers; risks related to our contracts with government customers and receipt of government grants; risks related to any future acquisitions and other strategic transactions; the accuracy of our addressable market estimates; our ability to operate successfully a global business and adverse global economic conditions; our ability to comply with applicable anti-corruption, trade compliance and economic sanctions laws and regulations; our ability to perform our services in accordance with contractual requirements, regulatory standards and ethical considerations; the loss of more than one of our major customers; the ability or inability of our bookings to accurately predict our future revenue and our ability to realize the anticipated revenue reflected in our; lower utilization rates by our employees as a result of catastrophic events, including natural disasters and epidemic diseases; disruptions in the operations of the third-party providers who host our software solutions or any limitations on their capacity or interference with our use; any unauthorized access to or use of customer or other proprietary or confidential data or other breach of our cybersecurity measures, compliance with privacy and

------

cybersecurity laws and related contractual requirements; our ability to reliably meet our data storage and management requirements, or the experience of any failures or interruptions in the delivery of our services over the internet; our ability to comply with the terms of any licenses governing our use of third-party open source software; our ability to adequately enforce or defend our ownership and use of our intellectual property and other proprietary rights; any allegations that we are infringing, misappropriating or otherwise violating a third party's intellectual property rights; risks related to our indebtedness; any additional impairment of goodwill or other intangible assets; and the other factors detailed under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" and elsewhere in our Securities and Exchange Commission ("SEC") filings, and reports, including the Form 10-K filed by the Company with the Securities and Exchange Commission on February 26, 2025, and subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events.

A Note on Non-GAAP Financial Measures

This press release contains "non-GAAP measures" which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Specifically, the Company makes use of the non-GAAP financial measures adjusted EBITDA, adjusted EBITDA margin adjusted net income (loss), adjusted diluted earnings per share, and constant currency ("CC") revenue, which are not recognized terms under GAAP. These measures should not be considered as alternatives to net income (loss), net income (loss) margin, or GAAP diluted earnings per share or revenue as measures of financial performance or any other performance measure derived in accordance with GAAP and should not be considered a measure of discretionary cash available to the Company to invest in the growth of its business. The presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the Company's results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

You should refer to the footnotes below as well as the "Reconciliation of Non-GAAP Financial Measures" section in this press release below for a further explanation of these measures and reconciliations of these non-GAAP measures in specific periods to their most directly comparable financial measure calculated and presented in accordance with GAAP for those periods.

Management uses various financial metrics, including total revenues, income (loss) from operations, net income (loss), and certain non-GAAP measures, such as adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted diluted earnings per share and CC revenue, to make budgeting decisions, to make

------

certain compensation decisions, and to compare the Company's performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company's business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance.

Management believes that adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted diluted earnings per share, and CC revenue are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, these non-GAAP measures are frequently used by analysts, investors, and other interested parties to evaluate and assess performance. Furthermore, our business has operations outside the United States that are conducted in local currencies. As a result, the comparability of the financial results reported in U.S. dollars is affected by changes in foreign currency exchange rates. We adjust revenues for constant currency to provide a framework for assessing how our business performed excluding the effect of foreign currency rate fluctuations and we believe it is helpful for investors to present operating results on a comparable basis period over period to evaluate its underlying performance.

(1) CC revenue excludes the effects of foreign currency exchange rate fluctuations by assuming constant foreign currency exchange rates used for translation. Current periods revenue reported in currencies other than U.S. Dollars are converted into U.S. Dollars at the average exchange rates in effect for the comparable prior periods.

(2) Adjusted EBITDA represents net income excluding interest expense, provision for (benefit from) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, goodwill impairment, change in fair value of contingent consideration, acquisition and integration expense and other items not indicative of our ongoing operating performance. Adjusted EBITDA margin represents adjusted EBITDA divided by revenue.

(3) Adjusted net income and adjusted diluted earnings per share exclude the effect of equity-based compensation expense, amortization of acquisition-related intangible assets, goodwill impairment, change in fair value of contingent consideration, acquisition and integration expense, and other items not indicative of our ongoing operating performance as well as income tax provision adjustment for such charges.

In evaluating adjusted EBITDA, adjusted EBITDA margin, adjusted net income, and adjusted diluted earnings per share, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.

**Contacts:**

------

**Investor Relations Contact:** <br>David Deuchler<br>Gilmartin Group<br><u>ir@certara.com</u>

**Media Contact:**

Alyssa Horowitz

Pan Communications

certara@pancomm.com

------

**CERTARA, INC. AND SUBSIDIARIES**<br>**CONSOLIDATED STATEMENTS OF OPERATIONS**<br>**(UNAUDITED)**<br>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED DECEMBER 31,** | **THREE MONTHS ENDED DECEMBER 31,** | **TWELVE MONTHS ENDED DECEMBER 31,** | **TWELVE MONTHS ENDED DECEMBER 31,** |
|<br>**(IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA)** | **2025** | **2024** | **2025** | **2024** |
| Total revenue | $103648  | $100361  | $418838  | $385148  |
| Cost of revenues | 39171  | 38263  | 161126  | 154516  |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;Sales and marketing | 14016  | 13197  | 53720  | 47444  |
| &nbsp;&nbsp;Research and development | 11280  | 7772  | 41040  | 37105  |
| &nbsp;&nbsp;General and administrative | 23893  | 21141  | 85380  | 94221  |
| &nbsp;&nbsp;Depreciation and amortization expense | 14452  | 13985  | 56556  | 53593  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 63641 | 56095 | 236696 | 232363 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from operations | 836 | 6003 | 21016 | (1731) |
| Other income (expenses): |  |  |  |  |
| &nbsp;&nbsp;Interest expense | (5119) | (5004) | (19738) | (21520) |
| &nbsp;&nbsp;Net other income | 1373  | 1181  | 6338  | 6067  |
| Total other expenses | (3746) | (3823) | (13400) | (15453) |
| &nbsp;&nbsp;Income (loss) before income taxes | (2910) | 2180 | 7616 | (17184) |
| &nbsp;&nbsp;Provision (benefit) for income taxes | 2985  | (4397) | 9211  | (5133) |
| Net income (loss) attributable to common stockholders: | $(5895) | $6577 | $(1595) | $(12051) |
| Net income per share attributable to common stockholders: |  |  |  |  |
| &nbsp;&nbsp;Basic | $(0.04) | $0.04  | $(0.01) | $(0.08) |
| &nbsp;&nbsp;Diluted | $(0.04) | $0.04  | $(0.01) | $(0.08) |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;Basic | 159281100  | 160891458  | 160394418  | 160392805  |
| &nbsp;&nbsp;Diluted | 159281100  | 161265650  | 160394418  | 160392805  |

---

------

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CERTARA, INC. AND SUBSIDIARIES** <br>**CONSOLIDATED BALANCE SHEETS** <br>**(UNAUDITED)** <br>

---

| | | |
|:---|:---|:---|
| **(IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA)** | **DECEMBER 31, 2025** | **DECEMBER 31, 2024** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $189392  | $179183  |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances for credit losses of $2,235 and $2,164 respectively | 103525  | 102189  |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 22202  | 29480  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 315119  | 310852  |
| Other assets: |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 1853  | 2167  |
| &nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 11939  | 13841  |
| &nbsp;&nbsp;&nbsp;Goodwill | 773311  | 757038  |
| &nbsp;&nbsp;&nbsp;Intangible assets, net of $415,804 and $338,809, respectively | 447476  | 485214  |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | 5242  | 3961  |
| &nbsp;&nbsp;&nbsp;Other long-term assets | 1642  | 2031  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1556582  | $1575104  |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $3426  | $3502  |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 67131  | 56451  |
| &nbsp;&nbsp;&nbsp;Current portion of deferred revenue | 75412  | 77829  |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt | 2963  | 3000  |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 4453  | 5306  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 153385  | 146088  |
| Long-term liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Deferred revenue, net of current portion | 2350  | 1049  |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | 34366  | 40421  |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities, net of current portion | 8438  | 11166  |
| &nbsp;&nbsp;&nbsp;Long-term debt, net of current portion and debt discount | 290131  | 292425  |
| &nbsp;&nbsp;&nbsp;Other long-term liabilities | 5117  | 25299  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 493787  | 516448  |
| Commitments and contingencies  |  |  |
| Stockholders' equity |  |  |
| Preferred shares, $0.01 par value, 50,000,000 and no shares authorized as of December 31, 2025 and 2024, respectively, no shares issued and outstanding as of December 31, 2025 and 2024, respectively | —  | —  |
| Common shares, $0.01 par value, 600,000,000 shares authorized, 164,005,450 and 161,958,810 shares issued as of December 31, 2025 and 2024, respectively; 159,139,562 and 161,009,112 shares outstanding as of December 31, 2025 and 2024, respectively | 1641  | 1620  |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 1255653  | 1216925  |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (129876) | (128281) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income(loss) | 2040  | (13424) |
| &nbsp;&nbsp;&nbsp;Treasury stock at cost,4,865,888 and 949,658 shares at December 31, 2025 and 2024, respectively | (66663) | (18184) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 1062795  | 1058656  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1556582  | $1575104  |

---

------

**CERTARA, INC. AND SUBSIDIARIES**<br>**CONSOLIDATED STATEMENTS OF CASH FLOWS**<br>**(UNAUDITED)** <br>

---

| | | |
|:---|:---|:---|
| | **TWELVE MONTHS ENDED DECEMBER 31,** | **TWELVE MONTHS ENDED DECEMBER 31,** |
|<br>**(IN THOUSANDS)** | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net loss | $(1595) | $(12051) |
| Adjustments to reconcile net loss to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 75162  | 68033  |
| &nbsp;&nbsp;Amortization of debt issuance costs | 568  | 1035  |
| &nbsp;&nbsp;Provision for credit losses | 1144  | 1464  |
| &nbsp;&nbsp;Equity-based compensation expense | 33079  | 34774  |
| &nbsp;&nbsp;Change in fair value of contingent considerations | (3597) | 8089  |
| &nbsp;&nbsp;Deferred income taxes | (8321) | (12695) |
| &nbsp;&nbsp;Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 428  | (16225) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (902) | (2873) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses, and other liabilities | 4403  | (4765) |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenues | (3018) | 13834  |
| Other operating activities, net | (1026) | 1846  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 96325 | 80466 |
| **Cash flows from investing activities:** |  |  |
| Capital expenditures | (1760) | (1625) |
| Capitalized software development costs | (24796) | (19416) |
| Business acquisitions, net of cash acquired | —  | (91327) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (26556) | (112368) |
| **Cash flows from financing activities:** |  |  |
| Common stock repurchase program | (42610) | —  |
| Proceeds from borrowings on term loan debt | —  | 6305  |
| Payment of debt issuance costs | —  | (1216) |
| Payments on long-term debt obligations | (2991) | (2255) |
| Payments for business acquisition related contingent consideration | (13230) | (15156) |
| Payment of taxes on shares and units withheld for employee taxes | (5155) | (8688) |
| Net cash used in financing activities | (63986) | (21010) |
| Effect of foreign exchange rate on cash and cash equivalents | 4426  | (2856) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash and cash equivalents | 10209 | (55768) |
| Cash and cash equivalents at beginning of period | 179183  | 234951  |
| Cash and cash equivalents at end of period | $189392 | $179183 |

---

------

NON-GAAP FINANCIAL MEASURES

The following table reconciles net income (loss) to Adjusted EBITDA:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED** <br>**DECEMBER 31,** | **THREE MONTHS ENDED** <br>**DECEMBER 31,** | **TWELVE MONTHS ENDED** <br>**DECEMBER 31,** | **TWELVE MONTHS ENDED** <br>**DECEMBER 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Net income (loss)(a) | $(5895) | $6577  | $(1595) | $(12051) |
| Interest expense(a) | 5119  | 5004  | 19738  | 21520  |
| Interest income(a) | (1565) | (1365) | (5720) | (9034) |
| (Benefit from) Provision for income taxes(a) | 2985  | (4397) | 9211  | (5133) |
| Depreciation and amortization expense(a) | 19104  | 18216  | 75162  | 68033  |
| Currency (gain) loss(a) | 282  | (182) | (891) | 2344  |
| Equity-based compensation expense(b) | 8190  | 7731  | 33079  | 34774  |
| Change in fair value of contingent consideration(d) | (385) | (3) | (3597) | 8089  |
| Acquisition-related expenses(e) | 1435  | 1275  | 3843  | 5426  |
| Integration expense(f) | 150  | —  | 150  | —  |
| Transaction-related expenses(g) | 928  | —  | 928  | 2625  |
| Severance expenses(h) | 2190  | —  | 2190  | 183  |
| Reorganization expense(i) | 116  | 279  | 1239  | 4223  |
| Loss on disposal of fixed assets(j) | (60) | 388  | (24) | 401  |
| Executive recruiting expense(k) | —  | 1  | 661  | 646  |
| Litigation and settlement expense(l) | (127) | —  | 119  | —  |
| Adjusted EBITDA | $32467  | $33524  | $134493  | $122046  |

---

------

The following table reconciles net income (loss) to adjusted net income:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED** <br>**DECEMBER 31,** | **THREE MONTHS ENDED** <br>**DECEMBER 31,** | **TWELVE MONTHS ENDED** <br>**DECEMBER 31,** | **TWELVE MONTHS ENDED** <br>**DECEMBER 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Net income (loss) (a) | $(5895) | $6577  | $(1595) | $(12051) |
| Currency (gain) loss(a) | 282  | (182) | (891) | 2344  |
| Equity-based compensation expense(b) | 8190  | 7731  | 33079  | 34774  |
| Amortization of acquisition-related intangible assets(c) | 14104  | 14390  | 56224  | 54431  |
| Change in fair value of contingent consideration(d) | (385) | (3) | (3597) | 8089  |
| Acquisition-related expenses(e) | 1435  | 1275  | 3843  | 5426  |
| Integration expense(f) | 150  | —  | 150  | —  |
| Transaction-related expenses(g) | 928  | —  | 928  | 2625  |
| Severance expenses(h) | 2190  | —  | 2190  | 183  |
| Reorganization expense(i) | 116  | 279  | 1239  | 4223  |
| Loss on disposal of fixed assets(j) | (60) | 388  | (24) | 401  |
| Executive recruiting expense(k) | —  | 1  | 661  | 646  |
| Litigation and settlement expense(l) | (127) | —  | 119  | —  |
| Income tax expense impact of adjustments(m) | (6060) | (5778) | (21408) | (28220) |
| Adjusted net income | $14868  | $24678  | $70918  | $72871  |

---

------

The following tables reconciles diluted earnings per share to adjusted diluted earnings per share:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED** <br>**DECEMBER 31,** | **THREE MONTHS ENDED** <br>**DECEMBER 31,** | **TWELVE MONTHS ENDED** <br>**DECEMBER 31,** | **TWELVE MONTHS ENDED** <br>**DECEMBER 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) (a) | $(0.04) | $0.04  | $(0.01) | $(0.08) |
| Currency (gain) loss(a) | -  | -  | (0.01) | 0.02  |
| Equity-based compensation expense(b) | 0.05  | 0.05  | 0.21  | 0.22  |
| Amortization of acquisition-related intangible assets(c) | 0.09  | 0.09  | 0.35  | 0.34  |
| Change in fair value of contingent consideration(d) | -  | -  | (0.02) | 0.05  |
| Acquisition-related expenses(e) | 0.01  | 0.01  | 0.02  | 0.03  |
| Integration expense(f) | -  | -  | -  | -  |
| Transaction-related expenses(g) | 0.01  | -  | 0.01  | 0.02  |
| Severance expenses(h) | 0.01  | -  | 0.01  | -  |
| Reorganization expense(i) | -  | -  | 0.01  | 0.03  |
| Loss on disposal of fixed assets(j) | -  | -  | -  | -  |
| Executive recruiting expense(k) | -  | -  | -  | -  |
| Litigation and settlement expense(l) |  |  |  | -  |
| Income tax expense impact of adjustments(m) | (0.04) | (0.04) | (0.13) | (0.18) |
| Adjusted Diluted Earnings Per Share | $0.09 | $0.15 | $0.44 | $0.45 |
| Basic weighted average common shares outstanding | 159281100  | 160891458  | 160394418  | 160392805  |
| Effect of potentially dilutive shares outstanding (n) | 518071 | 374192 | 500271 | 635547 |
| Adjusted diluted weighted average common shares outstanding | 159799171 | 161265650 | 160894689 | 161028352 |

---

------

The following tables reconcile revenues to the revenues adjusted for constant currency:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED DECEMBER 31,** | **THREE MONTHS ENDED DECEMBER 31,** | **THREE MONTHS ENDED DECEMBER 31,** | **Change** | **Change** |
| | **2025** | **2025** | **2024** | $**%** | $% |
| | **Actual** | **CC** | **Actual** | **Actual** | |
| | **(GAAP)** | **(non-GAAP)** | **(GAAP)** | **(GAAP)** | **(non-GAAP)** |
| | **(in thousands except percentage)** | **(in thousands except percentage)** | **(in thousands except percentage)** | **(in thousands except percentage)** | **(in thousands except percentage)** |
| Revenue |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Software | $46381  | $45695  | $42270  | 10% | 8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Services | 57267  | 56885  | 58091  | -1% | -2% |
| Total Revenue | $103648 | $102580 | $100361 | 3% | 2% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **TWELVE MONTHS ENDED DECEMBER 31,** | **TWELVE MONTHS ENDED DECEMBER 31,** | **TWELVE MONTHS ENDED DECEMBER 31,** | **Change** | **Change** |
| | **2025** | **2025** | **2024** | $**%** | $% |
| | **Actual** | **CC** | **Actual** | **Actual** | |
| | **(GAAP)** | **(non-GAAP)** | **(GAAP)** | **(GAAP)** | **(non-GAAP)** |
| | **(in thousands except percentage)** | **(in thousands except percentage)** | **(in thousands except percentage)** | **(in thousands except percentage)** | **(in thousands except percentage)** |
| Revenue |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Software | $183275  | $181795  | $155696  | 18% | 17% |
| &nbsp;&nbsp;&nbsp;&nbsp;Services | 235563  | 234213  | 229452  | 3% | 2% |
| Total Revenue | $418838 | $416008 | $385148 | 9% | 8% |

---

(a.)Represents a measure determined under GAAP.

(b.)Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.

(c.)Represents amortization costs associated with acquired intangible assets in connection with business acquisitions.

(d.)Represents expense associated with remeasuring fair value of contingent consideration of business acquisition.

(e.)Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions.

(f.)Represents integration costs related to post-acquisition integration activities.

(g.)Represents costs associated with our public offerings that are not capitalized, as well as debt issuance costs that are not deferred or treated as a contra-liability directly deducted from the carrying value of the associated debt liability.

(h.)Represents charges for severance provided to former executives.

(i.)Represents expenses related to reorganization, including legal entity reorganization and lease abandonment costs associated with the evaluation of our office space footprint.

(j.)Represents the gain/loss related to disposal of fixed assets.

(k.)Represents recruiting and relocation expenses related to hiring senior executives.

(l.)Represents expense related to a non-recurring employment litigation and settlement outside the normal course of business.

------

(m.)Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.

(n.)Represents potentially dilutive shares that were included from our GAAP diluted weighted average common shares outstanding.

<br>